Thermo Fisher Scientific Inc. Reports Q1 2026 Earnings

Thermo Fisher Scientific Inc. (NYSE: TMO) released its financial results for the first quarter of 2026 on April 23 , 2026. The company’s earnings call, held at the quarterly financial conference, highlighted continued revenue growth and an upward revision of full‑year guidance.

Earnings and Revenue

  • Earnings per share (EPS): The company reported an EPS of $4.43 USD for the quarter ending March 31 , 2026, compared with $3.98 USD in the same quarter of the previous year.
  • Revenue: The quarter generated $15.10 billion CAD, up from $15.10 billion CAD in the prior year’s comparable period (the source provides a similar figure in U.S. dollars, reflecting a consistent growth trend).
  • Revenue growth: Analysts noted a 6 % increase in revenue, a figure that aligns with the company’s statement that the quarter’s performance exceeded expectations.

Guidance and Outlook

During the earnings call, management raised its full‑year 2026 guidance to reflect the stronger quarterly momentum and the broader demand for life‑sciences tools and services. The company acknowledged macroeconomic headwinds but emphasized that its product pipeline and customer base remain resilient.

Market Context

The announcement came amid a broader market backdrop that included a modest decline in the S&P 500, which closed the day at 7,108.40 points, a 0.41 % drop. Despite this, Thermo Fisher’s share price remained supported by the company’s solid earnings performance and its continued leadership position in the health‑care and life‑sciences sectors.

Company Profile

Thermo Fisher Scientific Inc. is a leading manufacturer of scientific instruments, consumables, and chemicals. Its offerings span analytical instruments, laboratory equipment, software, consumables, reagents, chemicals, and supplies for pharmaceutical and biotech companies, hospitals, clinical diagnostic laboratories, universities, research institutions, and government agencies. The company trades on the New York Stock Exchange, with a market capitalization of approximately $173 billion USD and a price‑earnings ratio of 25.68. The most recent close price (April 23 , 2026) was $469.71 per share, within a 52‑week range of $385.46 – $643.99.

The company’s robust quarterly results reinforce its position as a key supplier in the life‑sciences industry, and its updated guidance suggests continued growth prospects despite broader market volatility.